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Arrest-defective protein 1, homolog A (ARD1A) N-acetyltransferase, 
which was initially identified in yeast, is involved in the regulation 
of the cell cycle and sporulation (1–4). Murine ARD1A (mARD1A
225) 
acetylates a lysine residue in the oxygen-dependent degradation 
domain  of  hypoxia-inducible  factor  1,  alpha  subunit  (HIF-1a), 
which enhances binding to the von Hippel–Lindau tumor sup-
pressor protein (VHL) and promotes the subsequent ubiquitina-
tion and proteasomal degradation of HIF-1a (5,6).
HIF-1 is a key factor involved in cellular adaptation to hypoxia (7). 
Under normoxic conditions, HIF-1a is posttranslationally modified 
and degraded (5,8–10). However, during hypoxia, HIF-1a is stabi-
lized and interacts with HIF-1b to form a functional HIF-1 complex 
(11). Transcriptional targets of HIF-1 include genes that promote 
angiogenesis and metastasis, most notably, the potent proangiogenic 
protein, vascular endothelial growth factor A (VEGFA) (7).
VEGFA modulates endothelial cell proliferation and vascular 
permeability  (12)  and  is  overexpressed  in  many  tumor  types   
(13–17), malignant carcinomas (18), and premalignant lesions (19). 
For example, a statistically significant positive association has been 
demonstrated between increased levels of HIF-1a and VEGFA in 
human colorectal carcinomas (18). In this study, we examined the 
role of mARD1A
225 in the regulation of both primary tumor growth 
and  metastatic  disease.  We  generated  mARD1A
225-expressing 
transgenic mice to determine whether mARD1A
225 plays a physio-
logically important role in regulating tumor growth via HIF-1a 
and VEGFA.
Methods
Construction  of  mARD1A
225  Expression  Vector  for 
Generation of Transgenic Mice
Sequences encoding a 9His-HRV2-9Myc tag were fused to full-
length mARD1A
225 cDNA and cloned into the pCAGGS vector 
under the control of a chicken beta-actin promoter. To investigate 
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  Background  Vascular endothelial growth factor A (VEGFA), a critical mediator of tumor angiogenesis, is a well-characterized 
target of hypoxia-inducible factor 1 (HIF-1). Murine arrest-defective protein 1A (mARD1A225) acetylates HIF-1a, 
triggering its degradation, and thus may play a role in decreased expression of VEGFA.
  Methods  We generated ApcMin/+/mARD1A225 transgenic mice and quantified growth of intestinal polyps. Human gastric 
MKN74 and murine melanoma B16F10 cells overexpressing mARD1A225 were injected into mice, and tumor 
growth and metastasis were measured. VEGFA expression and microvessel density in tumors were assessed 
using immunohistochemistry. To evaluate the role of mARD1A225 acetylation of Lys532 in HIF-1a, we injected 
B16F10-mARD1A225 cell lines stably expressing mutant HIF-1a/K532R into mice and measured metastasis. All 
statistical tests were two-sided, and P values less than .05 were considered statistically significant.
  Results  ApcMin/+/mARD1A225 transgenic mice (n = 25) had statistically significantly fewer intestinal polyps than ApcMin/+ mice 
(n = 21) (number of intestinal polyps per mouse: ApcMin/+ mice vs ApcMin/+/mARD1A225 transgenic mice, mean = 83.4 
vs 38.0 polyps, difference = 45.4 polyps, 95% confidence interval [CI] = 41.8 to 48.6; P < .001). The growth and 
metastases of transplanted tumors were also statistically significantly reduced in mice injected with mARD1A225-
overexpressing cells than in mice injected with control cells (P < .01). Moreover, overexpression of mARD1A225 
decreased VEGFA expression and microvessel density in tumor xenografts (P < .04) and ApcMin/+ intestinal polyps 
(P = .001). Mutation of lysine 532 of HIF-1a in B16F10-mARD1A225 cells prevented HIF-1a degradation and inhib-
ited the antimetastatic effect of mARD1A225 (P < .001).
 Conclusion  mARD1A225 may be a novel upstream target that blocks VEGFA expression and tumor-related angiogenesis.
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the effect of mARD1A
225-9His-9Myc fusion protein, 293T cells 
were transfected with pCAGGS-mARD1A
225-9His-9Myc or mock 
vector (pCAGGS-9His-9Myc) using Lipofectamine 2000 Reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s proto-
col. Transfected 293T cells were treated with proteasome inhib-
itor 10 µM MG132 under hypoxia for 4 hours, after which the cells 
were harvested and lysed. Then, we performed an acetylation assay 
of HIF-1a using an anti–acetyl lysine antibody and western blot 
analysis with a rabbit polyclonal anti–HIF-1a antibody (1:1000) in 
whole-cell extract.
Mouse Models and Generation of mARD1A
225 and Apc
Min/+/
mARD1A
225 Transgenic Mice
All mouse experiments were approved by the Institutional Animal 
Care and Use Committees (IACUC) of Ewha Women’s University 
and adhered to the National Research Council Guidelines. Apc
Min/+ 
mice, a spontaneous mouse model of intestinal tumorigenesis with a 
C57BL/6 background, were purchased from the Jackson Laboratory 
(Bar Harbor, ME). Eight-week-old male C57BL/6 and BALB/cSlc-
nude mice were purchased from the Jackson Laboratory and Japan 
Shizuoka Laboratory Center, Inc (Shizuoka, Japan), respectively. All 
mice were maintained in the Ewha Laboratory Animal Genomics 
Center under specific pathogen-free conditions.
Purified transgenic construct DNA was microinjected into the 
fertilized eggs collected from the superovulated C57BL/6 females. 
Genotyping was performed by polymerase chain reaction (PCR) 
and confirmed by Southern blot analysis of genomic DNA from 
the tail tissue of founder mice at 2 weeks of age. Eight founder 
mice were identified via PCR and Southern blot analysis (data not 
shown).  Among  these,  expression  of  mARD1A
225-His9-HRV2-
Myc9 protein was observed through the germline in three lines 
(0041, 0043, and 0046). The expression of mARD1A
225 protein was 
higher in major organs of the 0041 and 0043 lines than in those of 
the 0046 line (see Supplementary Figure 1, D, available online). 
To determine whether mARD1A
225 is associated with tumorigen-
esis, we crossed Apc
Min/+ males with mARD1A
225 transgenic (0041 
and  0043  lines)  females  to  generate  Apc
Min/+/mARD1A
225  trans-
genic mice. The PCR primers used were as follows: mARD1A
225-
forward, 5′_ GGA ATT CGC CGC CGC GAT GAA CAT_3′ 
and His9-HRV2-Myc9-reverse, 5′_ CAC CAC TAG TGT AAG 
CCG GG _3′; Apc
Min/+-forward, 5′_ TTC CAC TTT GGC ATA 
AGG C_3′ and reverse, 5′_ GCC ATC CCT TCA CGT TAG_3′; 
Apc
wild-forward, 5′_ TTC CAC TTT GGC ATA AGG C_3′ and 
reverse, 5′_ TTC TGA GAA AGA CAG AAG TTA_3′.
Reagents and Antibodies
MG132, a proteasome inhibitor, was purchased from Calbiochem 
(Darmstadt, Germany). Rabbit polyclonal anti–HIF-1a antibody 
was obtained from Cayman Chemical (Ann Arbor, MI). Rabbit 
polyclonal anti–von Willebrand Factor (vWF) antibody and mouse 
monoclonal  anti-CD34  antibody  were  purchased  from  Dako 
(Glostrup, Denmark). Mouse monoclonal anti-Myc antibody and 
rabbit polyclonal anti–acetyl lysine antibody were obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling 
(Beverly, MA), respectively. Mouse monoclonal VEGFA antibody 
(for Western blot) and rabbit polyclonal VEGFA antibody (for 
immunohistochemistry)  were  obtained  from  Novus  Biologicals 
cONteXtS AND cAVeAtS
Prior knowledge
Angiogenesis plays a central role in tumor growth and is mediated by 
vascular endothelial growth factor A (VEGFA), which is expressed in 
many tumor types. VEGFA transcription is initiated by hypoxia-induc-
ible factor 1a (HIF-1a). Arrest-defective protein 1A (ARD1A) induces 
the degradation of HIF-1a, resulting in lower VEGFA expression.
Study design
Growth  and  metastasis  of  intestinal  tumors  were  quantified  in 
transgenic mice expressing murine ARD1A. VEGFA expression and 
blood vessel proliferation in tumors were assessed in these mice 
relative to controls. The importance of HIF-1a degradation in sup-
pression of VEGFA expression was tested by mutation of the HIF-
1a acetylation site.
Contribution
Overexpression of ARD1A reduced the number and size of both 
primary tumors and metastases. In addition, ARD1A had an antian-
giogenic effect by decreasing VEGFA expression and blood vessel 
density in tumors. This effect was inhibited by mutation of a single 
acetylation site in HIF-1a.
Implications
The ARD1A protein may act as a novel antitumorigenic agent by 
blocking tumor-related angiogenesis.
Limitations
The effects of the mutant HIF-1a did not fully override the increased 
expression of ARD1A, suggesting that additional targets of ARD1A 
may be involved in regulating tumor growth. The murine ARD1A 
isoform has not yet been identified in human cell lines.
From the Editors
 
(Littleton,  CO)  and  Thermo  (Fremont,  CA),  respectively.  The 
rabbit polyclonal antibody against ARD1A was purchased from 
Dinona (Seoul, Korea) (6).
Cell Culture and Hypoxic Conditions
The murine melanoma cell lines B16F1 and B16F10 and human 
embryonic kidney 293T cells were purchased from the American 
Type Culture Collection (Manassas, VA). The human gastric can-
cer cell lines MKN74 and NUGC-3 were obtained from the Korea 
Cell Line Bank (Seoul, Korea). Those cell lines were maintained in 
Dulbecco’s modified Eagle medium (DMEM) (Gibco/Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Gibco/
Invitrogen), 100 U/mL penicillin, and 100 µg/mL streptomycin 
(Gibco/Invitrogen).  Human  umbilical  vein  endothelial  cells 
(HUVECs)  were  purchased  from  the  American  Type  Culture 
Collection and were grown in Medium 199 supplemented with 
20% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL strepto-
mycin, 3 ng/mL basic fibroblast growth factor, and 5 U/mL hep-
arin. All cells were maintained at 37°C in a 5% carbon dioxide 
humidified incubator.
To  generate  hypoxic  conditions,  murine  B16F10  melanoma 
and human gastric MKN74 tumor cells were incubated in 5% CO2 
and  1%  O2  balanced  with  N2  in  a  hypoxic  chamber  (Forma 
Scientific, Marietta, OH). Hypoxia was also induced in B16F10 
and MKN74 cell lines by treatment with cobalt chloride (CoCl2; 428   Articles | JNCI  Vol. 102, Issue 6  |  March 17, 2010
Sigma-Aldrich, St Louis, MO) at a final concentration of 200 µM. 
Cells treated with 200 µM CoCl2 exhibited induction of HIF-1a 
and VEGFA.
Construction of Plasmid and Stable Cell Lines
Sequences encoding a 9His-HRV2-9Myc tag were fused to full-
length  mARD1A
225  cDNA  and  cloned  into  pcDNA3.1/His  C 
(Invitrogen) expressing a neomycin resistance gene. We inserted 
the SV40 early promoter puromycin resistance gene cassette at the 
PvuII and ApaI sites of the pcDNA3.1-HIF-1a/K532R vector (5). 
This construct drives the expression of both puromycin resistance 
genes.  Stable  mARD1A
225-expressing  cell  lines  were  generated 
with B16F1, B16F10, MKN74, and NUGC-3 cells. Those cell 
lines were transfected with pcDNA3.1/His C-mARD1A
225-His9-
HRV2-Myc9  vector  or  empty  vector  (pcDNA3.1/His  C-His9-
HRV2-Myc9), as a control, by using Lipofectamine 2000 Reagent 
(Invitrogen)  according  to  the  manufacturer’s  instructions. 
Transfected  cells  (B16F10,  B16F1,  and  MKN74)  were  treated 
with 2 mg/mL geneticin (Roche, Nutley, NJ) for 3 weeks, after 
which single geneticin-resistant colonies were selected for expres-
sion of mARD1A
225 in the B16F10 (clones A#1 and A#2), MKN74 
(clones A#3 and A#4), and B16F1 (clones A#5 and A #6) cell lines 
and expression of pcDNA3.1/His C-9His-HRV2-9Myc in mock 
cell lines (B16F10-mock, MKN74-mock, and B16F1-mock) as the 
control. Transfected NUGC-3 cells were cultured for 2 weeks in 
medium containing 2 mg/mL geneticin, after which the geneticin-
resistant cells were selected for expression of mARD1A
225(NUGC-
3-Ard) and pcDNA3.1/His C-His9-HRV2-Myc9 (NUGC-3-mock) 
in the NUGC-3 cells. These stable cells were not selected for a 
single clone and, as such, they formed a population with mixed 
geneticin-resistant  colonies.  Stable  HIF-1a/K532R–expressing 
cell  lines  were  generated  with  B16F10-mARD1A
225  cells  using 
Lipofectamine 2000. B16F10-mARD1A
225 cells and B16F10-mock 
cells  were  transfected  with  pcDNA3.1-HIF-1a/K532R-puro 
vector and empty vector (pcDNA3.1-puro), respectively, by using 
Lipofectamine 2000 Reagent (Invitrogen) according to the manu-
facturer’s instructions. Transfectants were treated with 1 µg/mL 
puromycin (Sigma-Aldrich) for 2 weeks, after which puromycin-
resistant colonies were selected for expression of HIF-1a/K532R 
in  B16F10-mARD1A
225  (clone  B16F10-mARD1A
225-HIF-1a/
K532R) cells and expression of pcDNA3.1-puro in B16F10-mock 
cells (B16F10-mock-mock), as the control. These stable cells were 
not selected for a single clone and, as such, they form a mixed 
population of puromycin-resistant colonies.
Western Blot Analysis for mARD1A
225, HIF-1a, and VEGFA 
Protein
Murine  melanoma  B16F10  (B16F10,  B16F10-mock,  B16F10-
mARD1A
225 #1, and B16F10-mARD1A
225 #2) and human gastric 
MKN74 (MKN74, MKN74-mock, MKN74-mARD1A
225 #3, and 
MKN74-mARD1A
225 #4) tumor cells were exposed to hypoxia for 
4 and 6 hours, respectively, which resulted in the induction of 
HIF-1a. All cells were lysed in whole-cell extract buffer (10 mM 
HEPES, pH 7.9; 400 mM NaCl; 0.1 mM EDTA; 5% glycerol; 1 
mM  dithiothreitol  (DTT);  and  protease  inhibitors).  Tumors 
(derived  from  mice  injected  with  mARD1A
225-overexpressing 
B16F10 and MKN74 cells) were lysed and homogenized using a 
MICCRA  D-8  homogenizer  (Art-moderne  Labortechnik, 
Müllheim-Hügelheim, Germany) in protein extract buffer (20 mM 
HEPES, pH 7.9; 300 mM NaCl; 10 mM EDTA; 0.1% NP40; 100 
mM KCl; and protease inhibitors). Total protein (40 µg) was frac-
tionated on a 10% sodium dodecyl sulfate–polyacrylamide gel and 
transferred to nitrocellulose membranes (Amersham Biosciences, 
Piscataway, NJ). The membranes were probed with primary anti-
bodies  (rabbit  polyclonal  anti–HIF-1a,  mouse  monoclonal  anti-
Myc, and mouse monoclonal anti-VEGFA antibodies at 1:1000), 
followed by secondary antibodies (anti-rabbit and anti-mouse anti-
body, respectively, at 1:5000 [Zymed Laboratories, San Diego, CA]) 
conjugated  with  horseradish  peroxidase.  Protein–antibody 
complexes were detected with the ECL Plus system (Amersham 
Biosciences). Three independent experiments were performed.
Immunoprecipitation and In Vivo Acetylation Assay of 
HIF-1a
Murine  melanoma  B16F10  (B16F10,  B16F10-mock,  B16F10-
mARD1A
225 #1, and B16F10-mARD1A
225 #2) and human gastric 
MKN74 (MKN74, MKN74-mock, MKN74-mARD1A
225 #3, and 
MKN74-mARD1A
225  #4)  tumor  cells  were  treated  with  10  µM 
proteasome inhibitor MG132 under hypoxia for 4 and 6 hours, 
respectively.
All  cells  were  lysed  in  whole-cell  extract  buffer  (10  mM 
HEPES, pH 7.9; 400 mM NaCl; 0.1 mM EDTA; 5% glycerol;   
1 mM DTT; and protease inhibitors). Anti-acetyl lysine antibody 
(1 µg) was added to the lysate, followed by the addition of Protein 
A agarose (Upstate Biotech, Lake Placid, NY) in TEG reaction 
buffer (20 mM Tris–HCl at pH 7.4, 1 mM EDTA, 10% glycerol, 
1 mM DTT, and 150 mM NaCl), and the mixture was stirred 
overnight  at  4°C.  Immunoprecipitates  were  washed  in  TEG 
washing buffer (TEG reaction buffer containing 0.1% Triton-X 
100) and subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and Western blot analysis with a rabbit polyclonal 
anti–HIF-1a antibody as previously described. Three independent 
experiments were performed in duplicates.
Reverse Transcription–PCR Analysis to Test for VEGFA 
RNA Expression
Total  RNA  was  extracted  from  MKN74,  MKN74-mock,  and 
MKN74-mARD1A
225 cells, which were under hypoxic conditions for 
48 hours, using a RNA extraction kit (Invitrogen). Complementary 
DNA was synthesized from 4 µg of total RNA using an oligo-dT 
primer. The primers used for PCR were as follows: VEGFA forward, 
5′  _GAGAATTCGGCCTCCGAAACCATGAACTTTCTGCT_ 
3′  and  reverse,  5′_  GAGCATGCCCTCCTGCCCGGCTCA-
CCGC_ 3′; glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
forward,  5′_  ACCACAGTCCATGCCATCAC  _3′  and  reverse,   
5′_  TCCACCACCCTGTTGCTGTA_  3′.  Thirty  cycles  of  PCR 
were performed for amplification of VEGFA and GAPDH, and PCR 
products  were  detected  with  autoradiography.  Three  independent 
experiments were performed.
Quantification of VEGFA Expression by Enzyme-Linked 
Immunosorbent Assay
VEGFA  protein  levels  were  quantified  in  Apc
Min/+,  Apc
Min/+/
mARD1A
225 transgenic mouse serum (12 mice per group, 110 days jnci.oxfordjournals.org    JNCI | Articles 429
old),  and  in  conditioned  media  (1%  serum)  from  control  and 
mARD1A
225-expressing cells after treatment with CoCl2 at a final 
concentration of 200 µM to mimic hypoxia. Murine melanoma 
B16F10  (B16F10,  B16F10-mock,  B16F10-mARD1A
225  #1,  and 
B16F10-mARD1A
225 #2) and human gastric cancer cells MKN74 
(MKN74, MKN74-mock, MKN74-mARD1A
225 #3, and MKN74-
mARD1A
225 #4) were treated with 200 µM CoCl2 for 4 and 48 
hours, respectively. VEGFA levels were assayed with a commer-
cially available mouse and human enzyme-linked immunosorbent 
assay  kit  (R&D  Systems,  Minneapolis,  MN)  according  to  the 
manufacturer’s instructions. Three independent experiments were 
performed using conditioned media, each sample in duplicates. Of 
the three experiments, one experiment was performed for mouse 
serum with two replicates for each of 12 mice per group. Serial 
dilutions  of  a  purified  recombinant  mouse  or  human  VEGFA 
preparation with a known concentration were used to generate a 
standard curve. The total protein concentration in each condi-
tioned  medium  was  determined  with  Bio-Rad  (Hercules,  CA) 
protein assay reagent using bovine serum albumin to generate a 
standard curve.
Collection of Conditioned Media
mARD1A
225-overexpressing MKN74 stable cell lines were grown 
in T75 flasks with 10% fetal bovine serum. After seeding, cells 
were  incubated  for  24  hours,  washed  gently  with  serum-free 
DMEM medium, and incubated with 4 mL of DMEM. MKN74, 
MKN74-mock, and MKN74-mARD1A
225 (A#3 and A#4) cells and 
MKN74-mARD1A
225 cells transfected with HIF-1a/K532R were 
exposed  to  hypoxia  for  48  hours  using  hypoxic  chamber.  Also, 
MKN74-mARD1A
225 cells were treated with 10 ng/mL recombi-
nant human VEGFA protein (Sigma-Aldrich) after hypoxic condi-
tion. Conditioned media was collected, filtered, and stored at 4°C.
Tube Formation Assay
For the tube formation assay, 48-well plates were coated with cold 
Matrigel (BD Biosciences, Bedford, MA), which was allowed to 
polymerize at 37°C for 30 minutes. HUVECs were seeded (5 × 10
4 
cells per well) onto Matrigel with 500 µL filtered conditioned me-
dium  from  MKN74,  MKN74-mock,  and  MKN74-mARD1A
225 
(A#3 and A#4) cells; MKN74-mARD1A
225 cells treated with 10 ng/
mL  recombinant  human  VEGFA  protein;  and  MKN74-
mARD1A
225 cells transfected with  HIF-1a/K532R. Tube forma-
tion was assessed after 6 hours and quantified by determining the 
number of branching points. Each experiment was performed in 
three replicates.
Transwell Migration Assay
HUVEC  migration  was  performed  with  the  Transwell  system 
(Corning, Inc, Corning, NY), which allows cells to pass through a 
polycarbonate  membrane  with  a  pore  size  of  8  µm  in  24-well 
plates. The lower surface of the filter was coated with 20 µL of type 
I collagen (0.5 mg/mL). Cells were detached, counted, and plated 
at a concentration of 5 × 10
4 cells per well in the upper chamber 
with conditioned medium, and the lower chamber was filled with 
600 µL of conditioned medium to serve as the chemoattractant. 
After 6 hours of incubation, migrating cells were counted under 
microscope. Each experiment was performed in three replicates.
Tumor Cell Invasion Assay into Matrigel
Invasion  assays  were  performed  using  the  Transwell  system 
(Corning, Inc) with a polycarbonate membrane filter (6.5 mm di-
ameter, 8 µm pore size). The upper surface of the filter was coated 
with  20  µL  of  Matrigel  (0.3  mg/mL;  BD  Biosciences)  and  the 
lower side with 20 µL of type I collagen (0.5 mg/mL). HUVECs 
(5 × 104 cells per well) were detached from tissue culture plates, 
washed, resuspended in conditioned medium, and added to the 
upper compartment of the invasion chamber. Conditioned media 
were  added  to  the  lower  compartment.  Conditioned  media  of 
MKN74  cells  served  as  a  negative  control.  Matrigel  invasion 
chambers were incubated at 37°C for 24 hours in 5% CO2. After 
incubation, the filter inserts were removed from wells, and cells on 
the  upper  side  of  the  filter  were  removed  using  cotton  swabs. 
Filters were fixed, mounted, and stained according to the manufac-
turer’s instructions. Cells invading the Matrigel and located on the 
underside of the filter were counted. Three to five invasion cham-
bers were used per condition. Values calculated were numbers of 
cells averaged over at least three filters.
Tumor Cell Growth and Morphology and Primary Tumor 
Growth and Metastasis in Mice
Growth  curves  were  determined  3  days  after  seeding  B16F1 
(B16F1,  B16F1-mock,  B16F1-mARD1A
225  #5,  and  B16F1-
mARD1A
225 #6; 5 × 10
4 cells per well), B16F10 (B16F10, B16F10-
mock, B16F10-mARD1A
225 #1, and B16F10-mARD1A
225 #2; 5 × 
10
4  cells  per  well),  and  MKN74  cell  lines  (MKN74,  MKN74-
mock, MKN74-mARD1A
225 #3, and MKN74-mARD1A
225 #4; 3 × 
10
4  cells  per  well)  in  triplicate  into  12-well  plates.  B16F1  and 
B16F10 cell line sizes were determined by fluorescence-activated   
cell sorter analysis. Cell morphology was examined by photography.
For tumor growth experiments, a total of 5 × 10
5 B16F10 cells 
(B16F10,  B16F10-mock,  B16F10-mARD1A
225  #1,  and  B16F10-
mARD1A
225 #2) in 200 µL of 1× phosphate-buffered saline (PBS) 
(n = 8 mice per group) was injected subcutaneously into C57BL/6 
mice.  In  addition,  a  total  of  2  ×  10
7  MKN74  cells  (MKN74, 
MKN74-mock, MKN74-mARD1A
225 #3, and MKN74-mARD1A
225 
#4; n = 10 mice per group) and 2 × 10
7 NUGC-3 cells (NUGC-3-
mock and NUGC-3-mARD1A
225-mix; n = 5 mice per group) in 
200 µL of PBS were injected subcutaneously into BALB/cSlc-nude 
mice. When the major axis of the tumors reached approximately 
10 mm in length, tumor measurements were initiated. Tumors 
were measured every 2–4 days with calipers to estimate the volume 
(0.5 × width
2 × length). Mice with necrotic tumors were killed by 
CO2  asphyxiation,  and  tumors  were  isolated  and  weighed.  For 
metastasis experiments, a total of 3 × 10
5 cells (B16F10, B16F10-
mock,  and  B16F10-mARD1A
225)  in  100  µL  of  PBS/5%  mouse 
serum (n = 8 mice per group) was injected into C57BL/6 mice via 
the tail vein. If any mouse in any group began to appear moribund, 
all mice in the entire experiment were killed together (day 19 after 
injection) by CO2 asphyxiation, and surface tumor nodules in the 
lung were counted under a dissecting microscope. In addition, a 
total  of  1  ×  10
6  cells  of  each  of  B16F10-mock  (n  =  40  mice), 
B16F10-mARD1A
225 (n = 31 mice), B16F10-mARD1A
225-HIF-1a/
K532R  (n  =  11  mice),  B16F10-mock-mock  (n  =  15  mice),  and 
B16F10-mock-HIF-1a/K532R cell lines (n = 15 mice) in 100 µL 
of PBS/5% mouse serum were injected into C57BL/6 mice via the 430   Articles | JNCI  Vol. 102, Issue 6  |  March 17, 2010
tail  vein.  Mice  were  killed  14  days  after  injection,  and  surface 
tumor  nodules  in  the  lung  were  counted  under  a  dissecting 
microscope. Finally, a total of 5 × 10
5 cells of B16F10 cell lines 
(B16F10,  B16F10-mock,  B16F10-mARD1A
225  #1,  and  B16F10-
mARD1A
225 #2) in 100 µL of PBS/5% mouse serum were injected 
into C57BL/6 mice via the tail vein (n = 9 mice per group), and 
overall survival was monitored.
Polyp Number Determination
For macroscopic assessment of adenoma formation, Apc
Min/+ (n = 
25) and Apc
Min/+/mARD1A
225 transgenic mice (0041 lines, n = 21; 
0043 lines, n = 9) were killed by CO2 asphyxiation at 110 days old 
(when they exhibited sufficient tumor volume and numbers), and 
the small intestine and colon were isolated. The small intestine was 
subdivided into three equal segments (duodenum, jejunum, and 
ileum), dissected longitudinally, rinsed, spread flat on paper, and 
photographed with a digital camera. Tumor frequency and size 
were determined using the image analysis program with a semiau-
tomated  reading  system,  AxioVision  (Carl  Zeiss,  Thornwood, 
NY).
Wound Healing Assay
B16F10 cell lines (B16F10, B16F10-mock, B16F10-mARD1A
225 
#1, B16F10-mARD1A
225 #2, B16F10-mARD1A
225-HIF-1a/K532R   
cells,  B16F10-mock-mock,  and  B16F10-mock-HIF-1a/K532R   
cells) were cultured as 80% confluent monolayers and wounded by 
removing strips 300–500 µm wide across the well with a sterile 
pipette tip. Wounded monolayers were washed twice to remove 
nonadherent cells. Thereafter, cells were incubated in the presence 
of 200 µM CoCl2 for 24 hours. In addition, cells were treated with 
3 µg/mL anti-mouse VEGFA antibody (B16F10, B16F10-mock, 
B16F10-mARD1A
225-HIF-1a/K532R  cells, B16F10-mock-mock, 
and B16F10-mock-HIF-1a/K532R  cells; R&D Systems) and 25 
ng/mL recombinant mouse VEGFA protein (B16F10-mARD1A
225 
cells; Sigma-Aldrich) for 24 hours, fixed, and photographed. Three 
independent experiments were performed, each in duplicates.
Histology
Intestinal  polyps  from  Apc
Min/+,  Apc
Min/+/mARD1A
225  transgenic 
mice, and tumor tissues (derived from mice injected with mAR-
D1A
225-overexpressing B16F10 and MKN74 cells) were removed, 
immediately fixed with 10% formalin, embedded in paraffin, and 
4-µm sections were stained with hematoxylin and eosin. Sections 
were deparaffinized in xylene and rehydrated in graded alcohol. 
Antigen  retrieval  was  performed  using  sodium  citrate  buffer. 
Sections were stained with mouse monoclonal anti-CD34 (1:100; 
Dako),  rabbit  polyclonal  anti-vWF  (1:400;  Dako),  rabbit  poly-
clonal anti-VEGFA (1:200; Thermo), and rabbit polyclonal anti-
ARD1A (1:200; Dinona) antibodies. Following incubation with the 
respective biotinylated secondary antibodies and horseradish per-
oxidase avidin D (Vector Laboratories, Burlingame, CA), sections 
were  visualized  with  the  peroxidase  substrate  kit  (DAB;  Vector 
Laboratories), followed by counterstaining with hematoxylin.
Microvessel Determination
Microvessels  were  detected  in  intestinal  polyps  from  Apc
Min/+, 
Apc
Min/+/mARD1A
225  transgenic  mice,  or  MKN74-mARD1A
225 
expressing tumor tissue using rabbit polyclonal anti-vWF (1:400; 
Dako) or mouse monoclonal anti-CD34 (1:100; Dako) antibodies, 
respectively. Vessels in four or six high-power fields from each of 
4–8 mice per group were scored for quantification.
Statistical Analysis
Data are expressed as means with 95% confidence intervals (CIs). 
Statistical significance was determined with the two-sided Mann–
Whitney U test or a two-way repeated measures analysis of vari-
ance (SPSS, version 12.0; Statistical Package for Social Sciences, 
Chicago, IL), where applicable. Survival of mice was assessed by 
the Kaplan–Meier method, and the difference in median time to 
death between groups was compared by log-rank tests (SPSS). All 
tests were two-sided. P values less than .05 were considered statis-
tically significant.
results
Effect of mARD1A
225 Overexpression on the Number and 
Size of Intestinal Polyps and Survival in Apc
Min/+ Mice
To determine the physiological relevance of mARD1A
225, we gen-
erated  a  transgenic  mouse  containing  a  C-terminal  9His-9Myc 
epitope-tagged  mARD1A
225  transgene  driven  by  the  beta-actin 
promoter (see Supplementary Figure 1, A, available online). The 
effect of the mARD1A
225-9His-9Myc fusion protein on stability 
and acetylation of HIF-1a was examined in 293T cells via acetyla-
tion assays. HIF-1a was acetylated in cells expressing mARD1A
225-
9His-9Myc fusion protein (lane 1) but not in mock cells (lane 2) 
(see Supplementary Figure 1, B, available online). Transgene ex-
pression in mARD1A
225 transgenic mice was confirmed by PCR 
and Southern blot, and expression in the lung, liver, and colon 
were established by Western blot with an anti-Myc antibody (see 
Supplementary Figure 1, C and D, available online).
To verify whether an increase of mARD1A
225 expression af-
fects  tumor  initiation  and/or  progression,  we  crossbred 
mARD1A
225 transgenic mice with a spontaneous mouse model of 
intestinal  tumorigenesis  (Apc
Min/+  mice)  to  generate  Apc
Min/+/
mARD1A
225  transgenic  mice  (see  Supplementary  Figure  1,  E, 
available online). At approximately 16 weeks of age, mice were 
killed and polyp numbers and sizes were measured. Gross inspec-
tion of polyps and examination of the small intestine with hema-
toxylin  and  eosin  staining  revealed  a  statistically  significant 
decrease in both polyp size and number (Figure 1, A and B). The 
total number of intestinal polyps per mouse in Apc
Min/+/mARD1A
225 
transgenic  mice  was  less  than  50%  of  that  in  Apc
Min/+  mice 
(Apc
Min/+ mice vs Apc
Min/+/mARD1A
225 mice, mean = 83.4 vs 38.0 
polyps, difference = 45.4 polyps, 95% CI = 41.8 to 48.6, n = 25 
and n = 21, respectively; P < .001) (Figure 1, B). Notably, overex-
pression of mARD1A
225  was  associated  with  55%  reduction  in 
medium (1–2 mm) polyps (Apc
Min/+: mean = 52.3, 95% CI = 45.3 
to 59.3; Apc
Min/+/mARD1A
225: mean = 23.6 polyps, 95% CI = 17.6 
to 29.6; P < .001) and 79% reduction in large (>2 mm) polyps 
(Apc
Min/+: mean = 23.1 polyps, 95% CI = 15.6 to 30.6; Apc
Min/+/
mARD1A
225: mean = 4.8 polyps, 95% CI = 2.1 to 6.9; P < .001) 
(Figure 1, B). Comparison of polyp distribution in different seg-
ments  of  the  small  intestine  (duodenum,  jejunum,  and  ileum) 
revealed  similar  reductions  in  each  anatomic  region  (see jnci.oxfordjournals.org    JNCI | Articles 431
Figure 1. Effect of transgenic overexpression 
of mARD1A225 on intestinal tumorigenesis in 
ApcMin/+ mice. A) Representative images (top) 
and hematoxylin and eosin staining (bottom) 
of small intestinal polyps from 16-week-old 
Apc
Min/+  mice  and  Apc
Min/+/mARD1A
225  trans-
genic  mice  (Tg).  Magnification  ×100.  Scale 
bar = 200 µm. B) Tumor size distribution of 
polyps  in  the  small  intestine  from  Apc
Min/+ 
mice  (n  =  21  per  group)  and  Apc
Min/+/
mARD1A
225  Tg  (n  =  25  per  group).  Polyps 
were classified according to size in millime-
ters. Results are means with 95% confidence 
intervals  (error  bars).  *P  <  .001,  compared 
with  Apc
Min/+  mice,  determined  with  the 
two-sided Mann–Whitney U test. C) Kaplan–
Meier  survival  plot  of  Apc
Min/+  (mean  =  141 
days, 95% confidence interval = 131 to 151, n 
=  10  per  group,  solid  line)  and  Apc
Min/+/
mARD1A
225 Tg (mean = 170 days, 95% confi-
dence interval = 150 to 191, n = 10 per group, 
dotted line). *P = .005, compared with Apc
Min/+ 
mice,  determined  with  log-rank  tests.  All 
statistical tests were two-sided.
Supplementary Table 1, available online). The inhibitory effect 
of mARD1A
225 on intestinal tumorigenesis was confirmed in a 
second Apc
Min/+/mARD1A
225 transgenic line (n = 9, P = .03, see 
Supplementary Figure 2, available online). Moreover, Apc
Min/+/
mARD1A
225 transgenic mice (n = 10) displayed a statistically sig-
nificant survival advantage with a median life span of 171 days 
(95%  CI  =  150  to  191,  P  =  .005,  log-rank  test)  compared   
with Apc
Min/+ mice (n = 10) with a median life span of 141 days 
(95% CI = 131 to 151) (Figure 1, C). These results suggest that 
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Effect of Reduced VEGFA Expression on Tumor 
Angiogenesis in ApcMin/+/mARD1A225 Transgenic Mice
To examine the antiangiogenic effect of mARD1A225 via reduction 
of VEGFA expression, we immunostained intestinal polyps with 
the anti-mARD1A225 (Figure 2, A, top row panels, brown stain) and 
anti-VEGFA antibodies (Figure 2, A, second row panels, brown 
stain). VEGFA expression was statistically significantly decreased 
in  intestinal  polyps  from  ApcMin/+/mARD1A225  transgenic  mice 
compared  with  those  from  ApcMin/+  mice  (number  of  VEGFA-
positive cells per field, ApcMin/+ mice: mean = 104.7, 95% CI = 92 
to 117.4; ApcMin/+/mARD1A225: mean = 30.9, 95% CI = 23.4 to 38.4, 
n = 8; P = .001) (Figure 2, B) and in serum (ApcMin/+ mice: mean = 
30.2 pg/mL, 95% CI = 23.2 to 37.2; Apc
Min/+/mARD1A
225: mean = 
20.4 pg/mL, 95% CI = 14.8 to 26, n = 12; P = .023) (Figure 2, C). 
Microvessel density of polyps was quantified by immunostaining 
with an antibody specific for the endothelial marker, vWF (Figure 
2, A, four lower panels). Notably, vWF-positive vessels of intesti-
nal polyps from Apc
Min/+/mARD1A
225 transgenic mice were statisti-
cally significantly reduced compared with those of polyps from 
Apc
Min/+ mice (number of vessels per field, Apc
Min/+ mice: mean = 
63.8, 95% CI = 53.9 to 73.8; Apc
Min/+/mARD1A
225: mean = 23.7, 
95% CI = 16.5 to 7.2, n = 8; P = .001) (Figure 2, D). The data 
indicate that mARD1A
225 inhibits tumor angiogenesis by reducing 
VEGFA expression in intestinal polyps of Apc
Min/+ mice.
Figure 2. Effect of transgenic overexpression 
of mARD1A
225 on neovascularization and vas-
cular endothelial growth factor A (VEGFA) ex-
pression  in  intestinal  polyps  in  Apc
Min/+/
mARD1A
225  transgenic  mice.  A) 
Immunohistochemical analysis of mARD1A
225 
(top  row),  VEGFA  (second  row),  and  von 
Willebrand Factor (vWF, third row) in intestinal 
polyps of Apc
Min/+ mice and Apc
Min/+/mARD1A
225 
transgenic mice at 16 weeks of age (n = 8 mice 
per group). Magnification ×200. Scale bars = 
100 µm. Higher magnification of the selected 
area  (third  row,  yellow  boxes)  on  vWF  with 
vessels  indicated  by  red  arrows  within  the 
polyps  (bottom  row).  Magnification  ×400. 
Scale bar = 20 µm. B) The numbers of VEGFA-
positive cells in polyps are presented as means 
with  95%  confidence  intervals  (error  bars). 
VEGFA-positive cells in four high-power fields 
(×200) from each of the eight mice per group 
were scored for quantification. *P = .001, com-
pared with the number of VEGFA-positive cells 
in  Apc
Min/+  mouse  intestinal  polyps,  as  deter-
mined  with  the  two-sided  Mann–Whitney  U 
test.  C)  Concentrations  of  mouse  VEGFA 
protein in serum from ApcMin/+ mice and ApcMin/+/
mARD1A225 transgenic mice, respectively (n = 
12 mice per group). VEGFA protein levels were 
quantified  by  enzyme-linked  immunosorbent 
assay (ELISA). The experiment was performed 
in two replicate for each of 12 mice per group. 
The  levels  of  VEGFA  protein  in  serum  are   
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Effect of mARD1A
225 on Primary Tumor Growth
To  determine  the  in  vivo  effects  of  mARD1A
225  expression  on 
primary tumor growth, we used a xenograft tumor model in which 
syngeneic or nude mice were injected subcutaneously with mAR-
D1A
225-expressing murine B16F10 melanoma and human gastric 
MKN74  tumor  cells,  respectively.  These  cell  lines  were  estab-
lished from single clones expressing different levels of mARD1A
225 
protein (see Supplementary Figure 3, A, available online). Clonal 
cell lines did not display statistically significant differences in pro-
liferation (see Supplementary Figure 3, B, available online), cell 
size (see Supplementary Figure 3, C, available online), or morpho-
logical  teratism  under  normoxic  conditions  (see  Supplementary 
Figure 3, D, available online).
Tumors  were  isolated,  weighed,  and  measured  at  day  18 
(B16F10)  or  day  20  (MKN74).  Tumor  growth  was  statistically 
significantly suppressed in mice injected with B16F10-mARD1A
225 
and MKN74-mARD1A
225 cells (Figure 3, A and B). At day 18, for 
B16F10-mARD1A
225 cells, tumor volumes were as follows: B16F10, 
mean  =  2989.5  mm
2,  95%  CI  =  1502  to  4477;  B16F10/mock,   
mean  =  2851.9  mm
2,  95%  CI  =  2547.1  to  3156.8;  B16F10/
mARD1A
225 #1, mean = 1734.1 mm
2, 95% CI = 1053.1 to 2415.2; 
B16F10/mARD1A
225 #2, mean = 1255.4 mm
2, 95% CI = 901 to 
1609.7 (n = 8 per group, P = .003, clone A#1, P < .001, clone A#2) 
(Figure 3, A). For MKN74-mARD1A
225 cells, at day 20, tumor 
volumes were as follows: MKN74, mean = 279.7 mm
2, 95% CI = 
149.4 to 410; MKN74/mock, mean = 330.4 mm
2, 95% CI = 237.7 
to 423; MKN74/mARD1A
225 #3, mean = 60.5 mm
2, 95% CI = 38.9 
to 82.2; MKN74/mARD1A
225 #4, mean = 46.7 mm
2, 95% CI = 38 
to 55.5 (n = 10 per group, P = .007, clone A#3, P < .001, clone A#4) 
(Figure 3, B). An inhibitory effect of mARD1A
225 on primary tumor 
presented as means and 95% confidence inter-
vals (error bars) that are derived from the means 
of the individual mice (n = 12). *P = .023, com-
pared with the levels of VEGFA protein in ApcMin/+ 
mouse serum, as determined with the two-sided 
Mann–Whitney U test. D) The numbers of vWF-
positive  vessels  in  polyps  are  presented  as 
means and 95% confidence intervals (error bars). 
Vessels from five high-power fields (×400) from 
each of the eight mice per group were scored for 
quantification.  *P  =  .001,  compared  with  the 
number of vWF-positive vessels in Apc
Min/+ mouse 
intestinal  polyps,  as  determined  with  the 
two-sided Mann–Whitney U test. Tg = transgenic 
mice.
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growth was additionally observed with the human gastric tumor cell 
line, NUGC-3 (see Supplementary Figure 4, available online).
B16F10-mARD1A
225 tumor weights were 36% of the weight of 
control tumors on average (B16F10, mean = 3.02 mg, 95% CI = 
1.47 to 4.57; B16F10/mock, mean = 4.13 mg, 95% CI = 3.34 to 
4.91;  B16F10/mARD1A
225  #1,  mean  =  1.28  mg,  95%  CI  =  0.4   
to 2.16; B16F10/mARD1A
225 #2, mean = 1.35 mg, 95% CI = 0.5 to 
2.19; P = .021 for all comparisons) (Figure 3, C). Similarly, MKN74-
mARD1A
225 tumor weights were markedly reduced to less than 8% 
of control tumors (MKN74, mean = 0.3 mg, 95% CI = 0.161 to 
0.439; MKN74/mock, mean = 0.35 mg, 95% CI = 0.252 to 0.448; 
MKN74/mARD1A
225 #3, mean = 0.028 mg, 95% CI = 0.015 to 
0.04; MKN74/mARD1A
225 #4, mean = 0.018 mg, 95% CI = 0.013 
to 0.022; P = .017, clone A#3, P = .015, clone A#4) (Figure 3, D). 
Taken together, the data suggest that mARD1A
225 statistically sig-
nificantly inhibited the growth of transplanted tumors in vivo.
Effect of mARD1A
225 on Metastatic Lesions in the Lung
We determined the effect of mARD1A
225 on the incidence of lung 
nodule  formation  using  an  experimental  model  of  metastasis.   
We evaluated the number of lung nodules present at 3 weeks, fol-
lowing intravenous injection with equal numbers of B16F10 paren-
tal, B16F10-mock, and B16F10-mARD1A
225 cells (Figure 4, A–C). 
Mice  injected  with  B16F10-mARD1A
225  cells  contained  few  lung 
nodules, whereas numerous nodules were detected in groups injected 
with B16F10 parental or B16F10-mock cells. In mice injected with 
B16F10-mARD1A
225 cells, the number of surface tumor nodules was 
markedly decreased to less than 4% of the number of nodules in mice 
injected with B16F10 or B16F10-mock cells (number of lung nod-
ules per mouse, B16F10, mean = 181.75, 95% CI = 153.2 to 210.3; 
B16F10/mock,  mean  =  95,  95%  CI  =  62.5  to  127.5;  B16F10/
mARD1A
225 #1, mean = 6.5, 95% CI = 0 to 16.0, P = .006; B16F10/
mARD1A
225 #2, mean = 5, 95% CI = 0 to 11.5, P = .006) (Figure 4, 
A).  The  suppression  of  lung  metastases  in  mice  injected  with 
B16F10-mARD1A
225 cells was further confirmed by hematoxylin and 
eosin staining of lung sections (Figure 4, B). Moreover, the overall 
survival  of  mice  injected  intravenously  with  B16F10-mARD1A
225 
cells was statistically significantly longer than those injected with 
B16F10 or B16F10-mock cells. Mice began to die 11 days after the 
injection of control cells (B16F10, B16F10-mock). By day 25, 100% 
Figure  3.  Effect  of  mARD1A
225  on  primary 
tumor growth in mice. A) Representative im-
ages of primary tumor masses (left panel) and 
growth curves (right panel) are shown. C57BL/6 
mice  were  injected  subcutaneously  with 
B16F10  (open  diamond),  B16F10-mock  (open 
square),  or  B16F10-mARD1A
225  cells  (two 
clones;  closed  symbols).  Results  are  means 
and 95% confidence intervals (error bars). *P = 
.003, **P < .001, compared with mock control 
cells,  as  determined  with  two-way  repeated 
measures  analysis  of  variance  (ANOVA).  B) 
Representative  images  of  primary  tumor 
masses (left panel) and growth curves (right 
panel)  are  shown.  Nude  mice  were  injected 
subcutaneously with MKN74 (open diamond), 
MKN74-mock  (open  square),  or  MKN74-
mARD1A
225 cells (two clones; closed symbols). 
Results are means and 95% confidence inter-
vals (error bars). *P = .007, **P < .001, com-
pared with mock control cells, as determined 
with two-way repeated measures ANOVA. C) 
Tumor weights (n = 8 per group) were mea-
sured 3 weeks after inoculation with B16F10, 
B16F10-mock,  or  B16F10-mARD1A
225  cells. 
Results are means and 95% confidence inter-
vals  (error  bars).  *P  =  .021,  compared  with 
mock  control  cells,  as  determined  with  the 
two-sided  Mann–Whitney  U  test.  D)  Tumor 
weights (n = 10 per group) were measured 3 
weeks after inoculation with MKN74, MKN74-
mock,  and  MKN74-mARD1A
225  cells.  Results 
are means and 95% confidence intervals (error 
bars).  *P  =  .017,  **P  =  .015,  compared  with 
mock  control  cells,  as  determined  with  the 
two-sided Mann–Whitney U test. A#1= B16F10-
mARD1A225  #1;  A#2  =  B16F10-mARD1A225  #2; 
A#3  =  MKN74-mARD1A225  #3;  A#4  =  MKN74-
mARD1A225 #4.jnci.oxfordjournals.org    JNCI | Articles 435
Figure 4. Effect of mARD1A225 on lung nod-
ule  formation  in  mice.  A  and  B)  C57BL/6 
mice  were  injected  intravenously  with 
B16F10, B16F10-mock, or B16F10-mARD1A225 
cells.  The  incidence  of  lung  nodules  was 
determined 19 days after injection (n = 8 per 
group). A) Representative images of lungs 
(left).  Numbers  of  surface  tumor  nodules 
(right).  Results  are  means  and  95%  confi-
dence  intervals  (CIs)  (error  bars)  of  two 
independent  experiments  performed  with 
four mice per group. *P = .006, compared 
with the number of surface tumor nodules 
detected in B16F10-mock–injected mice, as 
determined  with  the  two-sided  Mann–
Whitney U test. B) Hematoxylin and eosin 
staining of 4-µm lung tissue sections excised 
from  mice  described  in  (A).  Magnification 
×50. Scale bar = 500 µm. C) Kaplan–Meier 
survival plot of C57BL/6 mice injected with 
B16F10 (mean = 16.7 days, 95% CI = 15.7 to 
17.7), B16F10-mock (mean = 18 days, 95% 
CI  =  15.5  to  20.5),  or  B16F10-mARD1A
225 
cells (A#1, mean = 23.9 days, 95% CI = 22.5 
to 25.3; A#2, mean = 22.7 days, 95% CI = 
20.8 to 24.5) (n = 9 per group). Comparisons 
were made with log-rank tests. All statistical 
tests were two-sided.
mortality was observed in mice with control cells, in contrast to 22% 
and 44% mortality in mice injected with B16F10/mARD1A
225 #1 (P 
< .001, log-rank test; n = 9 mice per group) and B16F10/mARD1A
225 
#2 (P = .002, log-rank test; n = 9 mice per group) cells, respectively 
(Figure 4, C). Thus, it appears that overexpression of mARD1A
225 
strongly suppresses the growth of metastases.
Effect of mARD1A
225 Overexpression on HIF-1a and VEGFA 
Expression In Vitro
To confirm the effects of mARD1A
225 on the stability and acetyla-
tion of HIF-1a in cancer cell lines, we stably expressed epitope-
tagged mARD1A
225 cDNA. In B16F10 and MKN74 cells transfected 
with mARD1A
225, a qualitative decrease in endogenous HIF-1a 
expression was evident during hypoxia (Figure 5, A). This inhibi-
tory effect of mARD1A
225 on HIF-1a expression was also observed 
in  clones  derived  from  B16F1  and  NUGC-3  tumor  cells  (see 
Supplementary Figure 5, A and B, available online).
To determine whether mARD1A
225 acetylates HIF-1a in tumor 
cells, we performed an acetylation assay using an anti–acetyl lysine 
antibody after treatment with the proteasome inhibitor MG132   
to  equalize  HIF-1a  protein  levels.  Acetylation  of  HIF-1a  was 
markedly  increased  in  B16F10-mARD1A225  and  MKN74-
mARD1A
225 cells (Figure 5, B), and in B16F1-mARD1A
225 cells 
(see Supplementary Figure 5, C, available online), compared with 
parental or mock-infected tumor cells.
Effect of mARD1A
225 on VEGFA Expression and 
Angiogenesis In Vitro
To determine the functional consequences of HIF-1a acetylation, 
we examined the expression of VEGFA, a known transcriptional 
target  of  HIF-1.  The  VEGFA  mRNA  level  was  appreciably 
decreased in MKN74-mARD1A
225 cells during hypoxia compared 
with that in MKN74-mock cells (Figure 5, C). Moreover, VEGFA 
protein expression was decreased in mARD1A
225-expressing tumor 
cell-conditioned medium, relative to control cells (Figure 5, D,   
P ≤ .05 for all comparisons). For B16F10 cells under normoxic 
condition, the concentration of VEGFA (in picograms) protein 
relative to total protein (in nanograms) was as follows: B16F10, 
mean  =  93.75  pg/ng  total  protein,  95%  CI  =  81.5  to  106.25; 
B16F10/mock,  mean  =  50  pg/ng,  95%  CI  =  24.53  to  75.47; 
B16F10/mARD1A
225  #1,  mean  =  2.08  pg/ng,  95%  CI  =  0  to   
6.16; B16F10/mARD1A
225 #2, mean = 8.3 pg/ng, 95% CI = 4.22 to 
12.38; in the hypoxic condition: B16F10, mean = 470.83 pg/ng, 
95% CI = 430 to 511.66; B16F10/mock, mean = 447.91 pg/ng, 436   Articles | JNCI  Vol. 102, Issue 6  |  March 17, 2010
Figure 5. Effect of mARD1A
225 on 
VEGFA  expression.  A)  B16F10, 
B16F10-mock,  and  B16F10-
mARD1A
225 cells were exposed to 
1%  O2  (4H)  or  21%  O2  (N)  for  4 
hours  (top).  MKN74-mock  and 
MKN74-mARD1A
225  cells  were 
exposed to 1% O2 (4H) or 21% O2 
(N) for 4 hours (bottom). HIF-1a 
and  mARD1A
225  protein  levels 
were  examined  by  Western  blot 
analysis.  Anti-Myc  antibody  was 
used  for  the  detection  of 
mARD1A
225.  B)  B16F10,  B16F10-
mock,  and  B16F10-mARD1A
225 
cells were exposed to 21% O2 (N) 
or  10  µM  MG132  and  1%  O2  for   
6  hours  (6H  +  MG132)  (top). 
MKN74,  MKN74-mock,  and 
MKN74-mARD1A
225  cells  were 
exposed  to  21%  O2  (N)  (not 
shown) or 10 µM MG132 and 1% 
O2  for  4  hours  (4H  +  MG132) 
(bottom). Cell lysates were immu-
noprecipitated with an anti–acetyl 
lysine antibody and subjected to 
Western  blot  analysis  with  an 
anti-HIF-1a antibody. The level of 
mARD1A
225  was  determined   
using  an  anti-Myc  antibody.  C) 
MKN74,  MKN74-mock,  and 
MKN74-mARD1A
225  cells  were 
exposed to 1% O2 (48H) or 21% O2 
(N)  for  48  hours.  Reverse   
transcription–polymerase  chain 
reaction  analysis  was  performed 
to  detect  gene  expression  using 
specific  primers  for  VEGFA  and 
glyceraldehyde  3-phosphate  de-
hydrogenase.  D)  VEGFA  protein 
levels  were  quantified  in  condi-
tioned  media  from  control  and 
mARD1A
225-expressing  cells 
treated with CoCl2 using enzyme-
linked  immunosorbent  assay 
ELISA. B16F10, B16F10-mock, and 
B16F10-mARD1A
225  cells  were   
cultured  in  the  absence  (N)  or   
presence  of  200  µM  CoCl2  for   
4  hours  (4H)  (left).  MKN74, 
MKN74-mock,  and  MKN74-
mARD1A
225 cells were cultured in 
the  absence  (N)  or  presence  of 
200 µM CoCl2 for 48 hours (48H) (right). Three independent experi-
ments were performed, each in two replicates. Results are means 
and 95% confidence intervals (error bars) derived from the means 
of individual experiments (n = 3). *P = .046, **P = .05, ***P = .021, 
compared with mock control cells, determined with the two-sided 
Mann–Whitney U test.
95% CI = 401.9 to 493.92; B16F10/mARD1A
225 #1, mean = 337.5 
pg/ng, 95% CI = 288 to 387; B16F10/mARD1A
225 #2, mean = 
297.9 pg/ng, 95% CI = 194.85 to 400.95 (Figure 5, D, left panel). 
In MKN74 cells under normoxic conditions, the concentration of 
VEGFA (in picograms) relative to total protein (in nanograms) was 
as follows: MKN74, mean = 2346.6 pg/ng, 95% CI = 2239.2 to 
2454.11; MKN74/mock, mean = 2517.7 pg/ng, 95% CI = 2350.1 
to 2685.3; MKN74/mARD1A
225 #3, mean = 1289.0 pg/ng, 95% CI = 
1066.6 to 1311.6; MKN74/mARD1A
225 #4, mean = 1652.0 pg/ng, 
95% CI = 1608.9 to 1695.2; in the hypoxic condition: MKN74, 
mean = 3451.7 pg/ng, 95% CI = 3182.9 to 3720.5; MKN74/mock, 
mean  =  3568.2  pg/ng,  95%  CI  =  3320.3  to  3816.1;  MKN74/
mARD1A
225 #3, mean = 2314.9 pg/ng, 95% CI = 2153.9 to 2475.9; 
MKN74/mARD1A
225 #4, mean = 2696.8 pg/ng, 95% CI = 2426.8 
to  2966.7  (Figure  5,  D,  right  panel).  The  data  confirm  that 
mARD1A
225 overexpression leads to decreased expression of HIF-
1a and VEGFA during hypoxia in both human and mouse cancer 
cell lines by promoting HIF-1a acetylation.
As an endothelial mitogen, VEGFA is a potent mediator of 
vascular permeability. To establish the antiangiogenic activity of 
mARD1A
225,  we  examined  endothelial  cell  activation  in  vitro. 
Capillary tube formation, migration, and invasion of HUVECs 
into Matrigel were all inhibited by hypoxic-conditioned media 
that were derived from mARD1A
225-expressing MKN74 tumors 
cells (Figure 6, A). To confirm the specificity of the VEGFA-
mediated  effect,  we  added  exogenous  VEGFA  protein  to  the jnci.oxfordjournals.org    JNCI | Articles 437
conditioned  media  or  used  media  derived  from  MKN74-
mARD1A
225 cells overexpressing HIF-1a/K532R (Figure 6, A), 
which enhanced tube formation, migration, and invasion of en-
dothelial  cells.  The  number  of  tubes  formed  per  field  was   
as  follows:  MKN74,  mean  =  35.7,  95%  CI  =  29.4  to  41.9; 
MKN74/mock, mean = 35, 95% CI = 30.1 to 39.9; MKN74/
mARD1A
225 #3, mean = 17.3, 95% CI = 11.8 to 22.9; MKN74/
mARD1A
225 #4, mean = 18.7, 95% CI = 14.1 to 23.2; MKN74-
mARD1A
225 #3+VEGFA, mean = 41.0, 95% CI = 36.9 to 45.1; 
MKN74-mARD1A
225 #4+VEGFA, mean = 44.7, 95% CI = 38.0 
to 51.3; MKN74-mARD1A
225 #3+HIF-1a/K532R, mean = 42, 
95% CI = 36 to 48; MKN74-mARD1A
225 #4+HIF-1a/K532R, 
mean = 41, 95% CI = 35 to 47 (Figure 6, A). The number of 
migrated cells per field was as follows: MKN74, mean = 278, 
95% CI = 263.2 to 292.8; MKN74/mock, mean = 289.7, 95%   
CI = 265.5 to 313.8; MKN74/mARD1A
225 #3, mean = 39.7, 95% 
CI = 37.1 to 42.3; MKN74/mARD1A
225  #4,  mean  =  31,  95%   
CI  =  26.5  to  35.5;  MKN74-mARD1A
225  #3+VEGFA,  mean  = 
271.7, 95% CI = 247 to 296.4; MKN74-mARD1A
225 #4+VEGFA, 
mean = 237.7, 95% CI = 198.2 to 277.1; MKN74-mARD1A
225 
#3+HIF-1a/K532R, mean = 219.3, 95% CI = 184.2 to 254.5; 
MKN74-mARD1A
225  #4+HIF-1a/K532R,  mean  =  276.3,  95% 
CI = 254.6 to 298.1 (Figure 6, B). The number of invasive cells 
per field was as follows: MKN74, mean = 253.3, 95% CI = 240.6 
to  266.1;  MKN74/mock,  mean  =  250.0,  95%  CI  =  242.1  to 
257.9; MKN74/mARD1A
225 #3, mean = 104.7, 95% CI = 102.3 
to 107; MKN74/mARD1A
225 #4, mean = 70.7, 95% CI = 54.7 to 
86.7; MKN74-mARD1A
225 #3+VEGFA, mean = 263.3, 95% CI 
=  245.3  to  281.4;  MKN74-mARD1A
225  #4+VEGFA,  mean  = 
269.7, 95% CI = 256.6 to 282.8; MKN74-mARD1A
225 #3+HIF-
1a/K532R, mean = 256.7, 95% CI = 236.3 to 277; MKN74-
mARD1A
225 #4+HIF-1a/K532R, mean = 271, 95% CI = 256.2 to 
Figure  6.  Effect  of  VEGFA  treatment  or 
HIF-1a/K532R  overexpression  on  tube 
formation,  migration,  and  invasion  by 
mARD1A
225.  A)  Human  umbilical  vein 
endothelial  cells  (HUVECs)  were  incu-
bated  for  6  hours  on  Matrigel  with 
hypoxic-conditioned media from MKN74, 
MKN74-mock,  and  MKN74-mARD1A
225 
(A#3 and A#4) cells (top left) and MKN74-
mARD1A
225  cells  treated  with  10  ng/mL 
recombinant  human  VEGFA  protein 
(A#3+VEGFA  and  A#4+VEGFA),  and 
MKN74-mARD1A
225 cells transfected with 
HIF-1a/K532R  (A#3+K532R  and 
A#4+K532R)  (bottom  left).  Scale  bar  = 
200 µm. Quantification of tube formation 
(right). Results are mean of three repli-
cates  from  one  experiment  and  their 
95% confidence intervals (error bars) (n = 
3). *P = .05, compared with the number 
of  MKN74-mock  cells;  #P  =  .05,  com-
pared  with  the  number  of  MKN74-
mARD1A
225 #3 or #4 cells, as determined 
with  the  two-sided  Mann–Whitney  U 
test.  B)  (Left)  HUVECs  and  conditioned 
media  were  added  to  transwells,  and 
migrating  cells  were  counted.  Data  are 
averaged over three independent experi-
ments. Scale bar = 100 µm. Quantification 
of migration (right). Results are mean of 
three  replicates  from  one  experiment 
and their 95% confidence intervals (error 
bars) (n = 3). *P = .05, compared with the 
number of MKN74-mock cells; #P = .05, 
compared  with  the  number  of  MKN74-
mARD1A225 #3 or #4 cells, as determined 
with  the  two-sided  Mann–Whitney  U 
test.  C)  Transwells  were  coated  with 
Matrigel. Cells were stained with hema-
toxylin and eosin. Representative micro-
scopic images illustrate HUVEC invasion 
(left). Scale bar = 100 µm. Quantification 
of invasion (right). Results are mean of 
three  replicates  from  one  experiment 
and their 95% confidence intervals (error 
bars) (n = 3). *P = .05, compared with the 
number of MKN74-mock cells; #P = .05, 
compared  with  the  number  of  MKN74-
mARD1A225 #3 or #4 cells, as determined 
with the two-sided Mann–Whitney U test. A#3 = MKN74-mARD1A225 
#3; A#4 = MKN74-mARD1A225 #4; A#3+VEGFA = MKN74-mARD1A225 
#3+  recombinant  human  VEGFA  protein;  A#4+VEGFA  =  MKN74-
mARD1A225  #4+  recombinant  human  VEGFA  protein;  A#3+K532R  = 
MKN74-mARD1A225 #3+HIF-1a/K532R; A#4+K532R = MKN74-mARD1A225 
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285.8 (Figure 6, C). The results strongly suggest that mARD1A
225 
suppresses angiogenesis by reducing VEGFA expression and in-
hibits  the  activation  of  endothelial  cells,  preventing  capillary 
tube formation, migration, and invasion (Figure 6, A–C, P = .05 
for all comparisons).
Effect of mARD1A
225 on HIF-1a Degradation and 
Neovascularization
To determine whether HIF-1a and VEGFA levels are reduced in 
mARD1A
225-expressing tumors, we analyzed expression of these 
proteins in tumors larger than 50 mm
2 and thus likely to be hypoxic 
in the center (20). Tumors that were derived from mARD1A
225-
expressing  B16F10  and  MNK74  cells  displayed  a  qualitative 
decrease in endogenous HIF-1a and VEGFA expression compared 
with  parental  and  mock-infected  cells  (Figure  7,  A  and  B). 
Similarly, immunohistochemical staining of MKN74-mARD1A
225-
expressing tumors displayed lower VEGFA expression than con-
trol tumors (MKN74, MKN74-mock) (Figure 7, C). To determine 
whether microvessel density was associated with VEGFA levels, we 
used an anti-CD34 antibody to identify endothelial cells and quan-
tify the number of microvessels in these tumors. CD34 staining 
revealed  that  MKN74-mARD1A
225–expressing  tumors  displayed 
lower microvessel density than those derived from mice injected 
with MKN74 or MKN74-mock cells (number of vessels per field: 
MKN74, mean = 28.2, 95% CI = 20.6 to 35.7; MKN74/mock, 
mean = 20.6, 95% CI = 16.6 to 24.5; MKN74/mARD1A
225 #3, 
mean = 12.8, 95% CI = 9.6 to 15.9 P = .043; MKN74/mARD1A
225 
#4, mean = 2.3, 95% CI = 1.0 to 3.6, P = .021) (Figure 7, D). These 
data indicate that mARD1A
225 inhibits tumor growth and angio-
genesis by repressing VEGFA activity through degradation of its 
upstream regulator, HIF-1a.
Identification of the Critical Lysine Residue in HIF-1a for 
mARD1A
225-Mediated Degradation
Previous studies reported that acetylation of lysine 532 of HIF-1a 
by mARD1A
225 leads to HIF-1a ubiquitination and degradation 
(5). To determine whether lysine 532 is necessary and sufficient for 
HIF-1a degradation, we mutated this residue and generated cell 
lines  stably  expressing  mutant  HIF-1a/K532R  in  B16F10-
mARD1A
225  cells  (B16F10-mARD1A
225-HIF-1a/K532R). 
Examination of HIF-1a expression and acetylation after 24 hours 
of hypoxia revealed HIF-1a levels in mARD1A
225-HIF-1a/K532R 
Figure 7. Effect of mARD1A
225 on neovas-
cularization.  A)  Western  blot  analysis  of 
HIF-1a and mARD1A
225 protein expression 
in transplanted B16F10 (left) and MNK74 
(right) tumor cells. B) Western blot analysis 
of  VEGFA  protein  expression  in  trans-
planted  B16F10  (left)  and  MNK74  (right) 
tumor cells. C) BALB/cSlc-nude mice were 
injected  subcutaneously  with  MKN74, 
MKN74-mock,  or  two  MKN74-mARD1A
225 
clones, A#3 and A#4. After 3 weeks, form-
alin-fixed  primary  tumor  sections  from 
each  mouse  were  prepared  and  stained 
with an anti-VEGFA antibody. The brown 
color signifies VEGFA in primary tumors. 
Magnification  ×400.  Scale  bar  =  50  µm. 
A#3  =  MKN74-mARD1A
225  #3;  A#4  = 
MKN74-mARD1A
225 #4. One representative 
image  of  five  per  cell  line  is  shown.  D) 
Anti-CD34  staining  of  xenograft  tumors 
derived  from  MKN74,  MKN74-mock,  and 
MKN74-mARD1A
225 cells, indicative of en-
dothelial  cells  (left).  Numbers  of  CD34-
positive vessels in primary tumors (right) 
expressed as means and 95% confidence 
intervals (error bars). Vessels from four or 
five fields from each of the five tumors per 
group were scored for quantification. *P = 
.043, **P = .021, compared with the number 
of CD34-positive vessels in tumors derived 
from MKN74-mock cells, as determined with 
the  two-sided  Mann–Whitney  U  test. 
Magnification ×200. Scale bar = 100 µm.jnci.oxfordjournals.org    JNCI | Articles 439
to be comparable to those in mock-infected tumor cell lines, sug-
gesting that mARD1A
225 is unable to acetylate and degrade HIF-
1a in the absence of lysine 532 (Figure 8, A).
To  confirm  the  functional  consequences  of  HIF-1a  overex-
pression, we measured VEGFA levels in the conditioned media of 
these cells (Figure 8, B). After 4 hours of hypoxia, VEGFA secre-
tion by mARD1A
225-HIF-1a/K532R–expressing cells was statisti-
cally significantly higher than that of mock-infected or parental 
cell lines, implying a critical role for lysine 532 in the regulation of 
HIF-1a stability (normoxic condition: B16F10/mock, mean = 50 
pg/mg, 95% CI = 24.53 to 75.47; B16F10/mARD1A
225 #1, mean = 
2.08 pg/mg, 95% CI = 0 to 6.16; B16F10/mARD1A
225/HIF-1a/
K532R, mean = 58.33 pg/mg, 95% CI = 22.74 to 93.92; hypoxic 
condition: B16F10/mock, mean = 447.91 pg/mg, 95% CI = 401.9 
to  493.92;  B16F10/mARD1A
225  #1,  mean  =  337.5  pg/mg,  95%   
CI = 288 to 387; B16F10/mARD1A
225/HIF-1a/K532R, mean = 
654.2 pg/mg, 95% CI = 509.9 to 798.5; P < .05 for all comparisons) 
(Figure 8, B).
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Figure 8. Effects of lysine 532 mutation in HIF-1a. A) HIF-1a protein 
levels  were  determined  by  Western  blot  analysis.  B16F10-mock, 
B16F10-mARD1A
225,  and  B16F10-mARD1A
225-HIF-1a/K532R  cells  were 
cultured in the absence (N) or presence of 200 µM CoCl2 for 24 hours 
(24H).  Similar  results  were  obtained  with  three  independent  experi-
ments. B) VEGFA levels (in picograms per milliliter) were quantified 
using  enzyme-linked  immunosorbent  assay.  B16F10,  B16F10-mock, 
B16F10-mARD1A
225,  and  B16F10-mARD1A
225-HIF-1a/K532R  cells  were 
cultured in the absence (N) or presence of 200 µM CoCl2 for 4 hours 
(4H).  Three  independent  experiments  were  performed,  each  in  two 
replicates. Results are means and 95% confidence intervals (error bars) 
derived from the means of the individual experiments (n = 3). *P = .05 
for all comparisons as determined with the two-sided Mann–Whitney U 
test.  C)  B16F10,  B16F10-mock,  B16F10-mARD1A
225,  and  B16F10-
mARD1A
225-HIF-1a/K532R cells were grown to 80% confluence. A linear 
injury  line  was  created  at  the  center  of  the  cultured  monolayer  by 
scraping with a sterile pipette tip. Cells were incubated in the presence 
of  200  µM  CoCl2  for  24  hours.  B16F10,  B16F10-mock,  and  B16F10-
mARD1A
225-HIF-1a/K532R cells were treated with 3 µg/mL anti-mouse 
VEGFA antibody. B16F10-mARD1A
225 cells were treated with 25 ng/mL 
recombinant  mouse  VEGFA  protein.  Images  of  cell  migration  (left). 
Quantification of cell migration (right). Migration distance (in microme-
ters); P = .004, determined with the two-sided Mann–Whitney U test. 
Three  independent  experiments  were  performed,  each  in  two  repli-
cates.  Results  are  means  and  95%  confidence  intervals  (error  bars) 
derived  from  the  means  of  the  individual  experiments  (n  =  3). 
Magnification ×100. Scale bar = 100 µm. D) C57BL/6 mice were injected 
intravenously with B16F10-mock (n = 40 mice), B16F10-mARD1A
225 (n = 
31 mice) and B16F10-mARD1A
225-HIF-1a/K532R cells (n = 11 mice). Lung 
nodule formation was determined 14 days after injection. Representative 
gross  images  of  lungs  are  shown  (left).  Numbers  of  surface  tumor   
nodules  per  mouse  (right).  Results  are  means  and  95%  confidence 
intervals (error bars). *P < .001, compared with the number of surface 
tumor  nodules  in  B16F10-mock–injected  mice,  #P  <  .001,  compared 
with  the  number  of  surface  tumor  nodules  in  B16F10-mARD1A
225–
injected mice, as determined with the two-sided Mann–Whitney U test. 
A#1  =  B16F10-mARD1A
225  #1;  A#2  =  B16F10-mARD1A
225  #2;  A#1/HIF 
K532R = B16F10-mARD1A
225 #1-HIF-1a/K532R; B16F10 + anti-VEGFA = 
B16F10 + anti-mouse VEGFA antibody; Mock + anti-VEGFA = B16F10-
Mock + anti-mouse VEGFA antibody; A#1/HIF K532R + anti-VEGFA = 
B16F10-mARD1A
225  #1-HIF-1a/K532R  +  anti-mouse  VEGFA  antibody; 
A#1+VEGFA  =  B16F10-mARD1A
225  #1  +  recombinant  mouse  VEGFA 
protein;  A#2+VEGFA  =  B16F10-mARD1A
225  #2  +  recombinant  mouse 
VEGFA protein.
Fig. 8 (continued).
VEGFA  is  an  important  endothelial  mitogen  but  has  also 
been reported to induce migration in a number of cell types, in-
cluding  tumor  cells.  Accordingly,  we  examined  the  ability  of 
VEGFA  generated  by  mARD1A
225-HIF-1a/K532R–expressing 
tumor cells to potentiate cell migration in a scratch assay (Figure 
8, C). A linear injury line was created at the center of a tissue 
culture dish, and tumor cell migration examined after 24 hours 
of incubation under hypoxic conditions. Regrowth and migration 
of B16F10 cells from the wound edge was inhibited by mARD1A
225 
(cell migration distances, B16F10/mock vs B16F10/mARD1A
225 
#1, mean = 591.4 vs 146.6 µm, difference = 444.8 µm, 95% CI = 
429.4 to 460.3; B16F10/mock vs B16F10/mARD1A
225 #2, mean = 
591.4 vs 94.7 µm, difference = 497.7 µm, 95% CI = 488.1 to 
505.4; P = .004 for all comparisons). As expected, increased ex-
pression  of  VEGFA  in  mutant  HIF-1a/K532R  cells  led  to 
enhanced  migration  compared  with  mARD1A
225-expressing   
cells  (B16F10/mARD1A
225  #1-HIF-1a/K532R  vs  B16F10/
mARD1A
225 #1, mean = 611.9 vs 146.6 µm, difference = 465.3 
µm, 95% CI = 462.5 to 468.2; P = .004). To confirm the speci-
ficity of VEGFA-mediated cell migration, we added a neutral-
izing  anti-mouse  VEGFA  antibody  or  recombinant  mouse 
VEGFA protein, which suppressed the migration of mARD1A
225-
HIF-1a/K532R–expressing tumor cells into the linear injury line 
(B16F10/mARD1A
225 #1-HIF-1a/K532R vs B16F10-mARD1A
225 
#1-HIF-1a/K532R + anti-VEGFA, mean = 611.9 vs 219.5µm, 
difference = 392.4 µm, 95% CI = 379.2 to 405.7; P = .004) but 
enhanced  migration  of  mARD1A
225  cells  (B16F10/mARD1A
225 
#1 vs B16F10-mARD1A
225 #1 + VEGFA protein, mean = 146.6 jnci.oxfordjournals.org    JNCI | Articles 441
vs 771.8 µm, difference = 625.2 µm, 95% CI = 616.8 to 633.6; 
B16F10/mARD1A
225  #2  vs  B16F10-mARD1A
225  #2  +  VEGFA 
protein, mean = 94.7 µm vs 652.2 µm, difference = 557.5 µm, 
95% CI = 534.8 to 580.3; P = .004 for all comparisons; Figure 8, 
C). The data clearly suggest that reduction of VEGFA is a crit-
ical  factor  in  mARD1A
225-induced  inhibition  of  B16F10  cell 
migration.
To determine the in vivo effects of the mARD1A
225-HIF-1a/
K532R  mutants,  we  examined  the  formation  of  lung  nodules 
after intravenous injection of B16F10-mock (n = 40), B16F10-
mARD1A
225 (n = 31), and B16F10-mARD1A
225-HIF-1a/K532R 
(n  =  11)  cells  into  syngeneic  C57BL/6  mice.  The  number   
of  surface  tumor  nodules  was  higher  in  mice  injected  with 
B16F10-mARD1A
225-HIF-1a/K532R cells compared with that 
in mice injected with B16F10-mARD1A
225 cells (number of lung 
nodules  per  mouse:  B16F10/mock  vs  B16F10/mARD1A
225  vs 
B16F10/mARD1A
225/HIF-1a/K532R, mean = 217.1 vs 16.38 vs 
111.8;  B16F10/mock  vs  B16F10/mARD1A
225,  difference  = 
200.72,  95%  CI  =  169.4  to  232.2;  B16F10/mARD1A
225  vs 
B16F10/mARD1A
225/HIF-1a/K532R, difference = 95.42, 95% 
CI = 57.4 to 133.4; P < .001 for all comparisons; Figure 8, D). 
We tested the activity of a mutant HIF-1a/K532R, which was 
stably expressed under normoxic conditions (see Supplementary 
Figure 6, A, available online). Increased expression of mutant 
HIF-1a/K532R in B16F10-mock cells led to enhanced migra-
tion  and  metastasis  compared  with  B16F10-mock-mock   
cells (see Supplementary Figure 6, B and C, available online). 
Therefore,  stabilization  of  HIF-1a  appears  to  reverse  the 
tumor-suppressive effect of mARD1A
225 on lung lesions. Based 
on these data, we propose that lysine 532 of HIF-1a is impor-
tant for HIF-1a degradation, ultimately leading to the regula-
tion of VEGFA expression.
Discussion
We demonstrate that the potent antitumor effects of mARD1A
225 
are mediated by HIF-1a degradation, resulting in reduced expres-
sion of its well-characterized target, VEGFA. Moreover, overex-
pression  of  mARD1A
225  leads  to  inhibition  of  tumorigenesis  in 
three different tumor models via reduction of VEGFA expression 
and its proangiogenic functions in both murine and human cancer 
cells.
The  Apc
Min/+  mice  have  been  widely  used  as  a  model  for 
studying early events in intestinal tumorigenesis. Recent reports 
indicate  that  VEGFA  expression  was  increased  and  correlated 
with adenomatous polyposis coli (APC) gene mutations in primary 
human colon tumors (19). Also, this model showed that short-
term treatment of Apc
Min/+ mice with an anti-VEGFA monoclonal 
antibody results in reduced tumor burden and vessel density of 
intestinal polyps (21). Similarly, targeted deletion of VEGFA in 
intestinal  epithelial  cells  of  Apc
Min/+  mice  induced  a  statistically 
significant  reduction  in  tumor  growth  (21),  suggesting  that 
VEGFA  plays  an  important  role  in  Apc
Min/+  intestinal  polyp 
growth. The offspring from a cross between the Apc
Min/+ mouse 
and  a  mouse  null  for  the  endogenous  anti–angiogenic  protein 
thrombospondin 1 (THBS1
2/2) showed a significant increase in 
polyp number and diameter (22), indicating a possible role for 
angiogenesis  in  polyp  development.  A  study  of  another  mouse 
model  of  intestinal  adenomas,  Apc
716,  which  reported  elevated 
VEGFA protein levels in polyps compared with normal intestinal 
epithelium control tissue, was also consistent with an association 
between  VEGFA  and  polyp  development  (23).  In  our  experi-
ments, VEGFA expression was decreased in intestinal polyps of 
Apc
Min/+/mARD1A
225 transgenic mice, which, in turn, led to sup-
pression of tumor growth and angiogenesis. Therefore, we pro-
pose  that  transgenic  overexpression  of  mARD1A
225  exerts  an 
important tumor-suppressive effect via inhibition of VEGFA in 
Apc
Min/+ mouse intestinal polyps.
Whereas the vast majority of tumors express VEGFA (24), it is 
clear that VEGFA regulation by HIF-1a plays a critical role in 
tumor angiogenesis and growth (25). Here, we show that overex-
pression of mARD1A
225 in both human gastric cancer and mouse 
melanoma cells induces a statistically significant reduction of HIF-
1a  protein  expression  and  consequent  production  of  VEGFA. 
Furthermore,  the  growth  of  lung  nodules  in  an  experimental 
model of lung metastases was markedly inhibited by overexpres-
sion  of  mARD1A
225  in  cancer  cells.  Expression  of  HIF-1a  and 
VEGFA triggered under conditions of intratumoral hypoxia was 
decreased by mARD1A
225 in B16F10 and MKN74 tumors. Our in 
vitro studies demonstrate that mARD1A
225 overexpression leads to 
suppression  of  VEGFA-mediated  endothelial  cell  proliferation, 
migration, and capillary tube formation. The data collectively sug-
gest  that  the  decrease  in  VEGFA  levels  induced  as  a  result  of 
degradation of HIF-1a by mARD1A
225 inhibits tumor growth and 
angiogenesis in vivo.
This study confirms the in vivo importance of a single lysine 
residue in regulating the stability of HIF-1a. To our knowledge, 
HIF-1a  is  the  only  known  target  of  the  acetyltransferase, 
mARD1A
225.  Our  analyses  of  the  mutant  HIF-1a  construct, 
HIF-1a/K532R, show that VEGFA overexpression is because of 
the stability of HIF-1a. However, the effects of the mutant HIF-
1a in tumor cells did not fully override the increased expression 
of mARD1A
225, such that the incidence of lung tumor lesions in 
our experimental model of lung metastases was higher than that 
in  mARD1A
225-overexpressing  cells  but  not  higher  than  in 
mock-infected tumor cells (Figure 8, D). This suggests that ad-
ditional targets of mARD1A
225 are involved in regulating tumor 
growth and/or progression. Other limitations of this study are 
that we only examined VEGFA expression as a measure of HIF-
1a activity. We also could not exclude the possibility of other 
HIF-1a-targets involved in tumor growth and/or progression. 
In addition, the mARD1A
225 isoform has not yet been identified 
in human cell lines. However, recent reports provide direct evi-
dence  for  an  inhibitory  effect  of  human  ARD1A  on  HIF-1a 
stability (26,27).
Our data collectively confirm the importance of mARD1A
225 in 
regulating tumor growth and development and provide evidence 
of its antitumor and antiangiogenic activities. Notably, mARD1A
225 
regulates  tumor  growth  via  degradation  of  HIF-1a  and  conse-
quent reduced expression of the proangiogenic protein, VEGFA. 
Therefore, we conclude that mARD1A
225 presents a novel target in 
the regulation of HIF-1a stability and may have potent therapeutic 
effects in combination with currently approved anti-VEGFA treat-
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